Xsight Labs Announces Availability of E1 – Revolutionizing the DPU Market with the Industry’s Unparalleled Fully Software-Defined Network Architecture
21.5.2025 14:00:00 CEST | Business Wire | Press Release
Xsight Labs, a leading fabless semiconductor company providing end-to-end connectivity for next-generation hyperscale, edge and AI data center networks, today announced availability of its Arm®-based E1-SoC for cloud and edge AI data centers. The E-Series is the only product of its kind to provide full control plane and data path programmability and is the industry’s highest performance software-defined DPU (Data Processing Unit). Xsight Labs is taking orders now for its E1-SoC and the E1-Server, the first-to-market 800G DPU.
E1 is the first SoC in the E-Series, Xsight Labs’ SDN (Software Defined Network) Infrastructure Processor product family of fully programmable network accelerators. Built on TSMC’s advanced 5nm process technology, the E1-SoC will begin shipping to customers and ecosystem partners.
“We are truly excited with the progress we have made with the E1-SoC in such a short timeframe,” said Eric Vallone, Xsight Labs Vice President of Business Development. “The performance we have seen since getting the E1 back from production is amazing. Given the unprecedented flexibility and performance the E1 delivers, we look forward to the opportunities that the E1 will create for our customers across a multitude of use cases.”
E1-Server: A High-Performance Edge Server System
The E1-Server is both an end-system solution and a comprehensive product development platform comprised of a single rack-unit system and associated software. The E1‑Server allows prototyping and proof-of-concept activities for engineering and product development teams, or it can be immediately deployed as a high-performance, stand-alone Edge Server System.
The E1-Server ships with a full complement of software tools and applications supporting a wide variety of use cases. Use cases for the E1-Server include edge computing, public cloud, content service provider infrastructure, wireless infrastructure, AI factory front and back-end networking, as well as secure enterprise infrastructure.
The E1-SoC is perfect for developing compute, networking, security, storage, smart switch and air-cooled edge inference (accelerator or GPU appliances) in smaller form factors like a traditional PCIe® Adapter Card. The E1-Server can be used as a system development platform for OEMs, ODMs, and CSP engineering teams to create their own solutions. Developers can use the Xsight Labs’ connectivity products for scaling out the E1-Server. Xsight Labs also offers the SDN programable X-Series Ultra Ethernet Consortium switching solutions as system or chip devices. The E1 and the X2 combine to allow Smart Switch and SDN all-layer (OSI L1 to L7) systems with 100% 112G SerDes connectivity offering the best-in-class processing and networking density per rack unit over all available silicon solutions.
“Xsight Labs is set to disrupt the DPU market with its innovative E-Series of software-defined, fully programmable network accelerators,” said Bob Wheeler, Principal Analyst, Wheeler’s Network. “Most existing DPUs started from legacy NIC designs resulting in constrained feature sets and proprietary software tools. The E1 breaks this paradigm as the first SoC of its kind to deliver the openness of an Arm server.”
Enabling Seamless Integration and Rapid Deployment
The E1 is designed with the goal of achieving Arm SystemReady compliance, meaning operating systems will work out-of-the-box, expediting time to deployment and reducing cost of development.
“As data centers evolve to meet rising demands in performance, efficiency, and security in the age of AI, DPUs have become a critical enabler,” said Dong Wei, Standards Architect and Fellow, Arm. “Built on the foundational compute of Arm Neoverse Compute Subsystems, Xsight Labs is setting new standards of performance with E1 while working toward SystemReady compliance and ensuring software interoperability.”
E1-SoC Key Features:
- Native support for Linux, DPDK, SPDK and XDP
- Up to 32/64 Arm Neoverse™ N2 v9.0-A cores
- Up to 4 DDR5 at 5200 MT/s with memory encryption (AES-XTS)
- 40 PCIe® 5.0 lanes, 10 dual-mode controllers, multi-host support
- Up to 800 Gbps networking throughput: 2x400G, 4x200G or 8x100G/50G/25G
For the full list of features, please see the E1-SoC Product Brief.
For ordering information, email sales@xsightlabs.com or visit https://xsightlabs.com/contact/.
About Xsight Labs
Xsight Labs is a fabless semiconductor company that enables end-to-end connectivity solutions for AI and hyperscale data centers. Xsight Labs’ technology delivers exponential bandwidth growth and unmatched versatility while lowering power and total cost of ownership. Founded in 2017, Xsight Labs is headquartered in Kiryat Gat, Israel, with additional offices in Tel Aviv and Haifa, and international offices in Yerevan, Armenia, as well as in Boston, Raleigh, and San Jose in the United States. For additional information, visit www.xsightlabs.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250521466002/en/
Contacts
Kevin Gaboury
xsightlabs@nereus-worldwide.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom